follicular cancer | Follicular lymphoma in relapse

Follicular lymphoma in relapse

This article recounts a personal experience, in no case should it be taken as an example, without a medical opinion and follow-up, each case being different.

May 2017. 3rd Relapse of follicular lymphoma (treated in 2007 chemo protocol R CHOP, then relapse in 2010 and re-treatment heavy in 2012 (Autograft, large chemo, sterile chamber etc.... then 2nd relapse in May 2014. Surveillance scanner at 3 months in September 2014: The adenopathies had in May 2014 and August 2014 (3 months) increased by + by 50%. So I was treated a 3rd time with monoclonal antibodies (MabThera) and as usual total remission.

 Relapse follicular lymphoma is presented as incurable. This series of relapses is part of the logic of this type of cancer.

In short, 3 years of Tranquility then may 2017 3rd relapse. The hematologist remains in therapeutic forbearance. A "critical" mass of adenopathies is generally expected to be treated.

Except that, in May, I get to know the metabolic treatments,..... I believe it first of all moderately, but the advantage of this type of cancer, its slowness, allows me-while officially being in forbearance-to test the alpha acid Lipoic + Hydroxycitrate... Between May and September 2017 I take this treatment more or less over the leg (I zap my capsules sometimes, and in addition, I did not order the biologically most effective formula of alpha lipoic acid. The Natural form – R-alpha lipoic.

Despite my laxity, the increase in adenopathies is only 24% over 4 months, whereas usually it is rather 50% in 3 months.

Compared to the medical criteria, this is a relative "stability", but which allows me to avoid treatment at this time. We remain in therapeutic abstention and a SCANNER is reprogrammed in January 2018.

I specify that between September 2017 and January 2018, I acquired the correct formula of R LIPOATE (6 capsules of 240 mg/day)

This scanner should have shown a significant increase compared to September 2017.

I quote the summary of the report: the examination compared to the one performed in September 2017 does not show an anomaly in the number and size of the axillary and metastasis cervical adenopathies. There is no MODIFICATION of the inguinal adenopathies. No lesions of recent appearance. "

For me it is clear, between September 2017 and January 2018 the evolution was completely blocked. I have RV at my blood on January 11th, and I think I'm going to stay in therapeutic forbearance. 
Thank you thank you. I ask you to share this testimonial on the site